73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Fisher & Paykel Healthcare Corp Ltd
Open
SectorReal estate
33.35
Overview
Share price change
24h
Min
33.35
Max
33.35
Income | -37M 187M |
|---|---|
Sales | -316M 965M |
P/E Sector Avg | 50.813 59.561 |
Dividend yield | 1.32 |
Profit margin | 19.353 |
Employees | 7,384 |
EBITDA | -335M 319M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +12.39% upside |
Market Cap | -229M 19B |
|---|---|
Previous open | 33.35 |
Previous close | 33.35 |
Fisher & Paykel Healthcare Corp Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Fisher & Paykel Healthcare Corp Ltd Forecast
Price Target
By TipRanks
12.39% upside
12 Months Forecast
Average 37.09 AUD 12.39%
High 42.8 AUD
Low 31 AUD
Based on 8 Wall Street analysts offering 12 month price targets forFisher & Paykel Healthcare Corp Ltd - Dist in the last 3 months.
Financials
$
About Fisher & Paykel Healthcare Corp Ltd
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Live chat